tirzepatide being discontinued The Impact of New FDA Regulations on Is Tirzepatide a Stimulant? Mechanism

No trial arm, no sub-study, no exploratory analysis tested five-day dosing intervals

At the moment, there is no clinical evidence that GLP-1 drugs treat endometriosis

Oral Semaglutide and Cardiovascular Outcomes in Patients With Type 2 Diabetes

ongoing monitoring is still needed Bariatric surgery may be considered for severe obesity Medications First-line medication Reduces CSF production Start low, increase gradually Side effects: tingling, carbonated drinks taste flat, kidney stones Alternative or addition to acetazolamide May help with headache Can cause weight loss (advantage in IIH) Side effects: cognitive slowing, tingling Furosemide Sometimes added to acetazolamide Monitor potassium GLP-1 Receptor Agonists (Emerging Treatment) GLP-1 medications (such as semaglutide, sold as Ozempic or Wegovy) are showing significant promise for IIH

DOI: 10.1136/bmj.s325 Never miss a breakthrough: Join the SciTechDaily newsletter